ALL ABOUT DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia and small lymphocytic lymphoma without 17p deletion.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia and small lymphocytic lymphoma without 17p deletion.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia and small lymphocytic lymphoma without 17p deletion.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia and small lymphocytic lymphoma without 17p deletion.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia and small lymphocytic lymphoma without 17p deletion.
The WHO launched clinical trials for Bundibugyo virus Ebola treatments and vaccines following outbreaks in the DRC and Uganda.
Read More
A Cochrane review of six trials found PSA screening likely reduces prostate cancer deaths by about two per 1,000 men screened.
Read More
CDC confirms first U.S. human H5N1 bird flu case linked to exposure to infected dairy cattle in a Texas farm worker.
Read More
CMS proposes a 3.1% payment increase for U.S. hospitals in 2027 and expands value-based quality reporting requirements.
Read More
The FDA warns against counterfeit semaglutide injections sold online after severe adverse events linked to fake Ozempic products.
Read More
No major hospital mergers, closures, or bankruptcies were confirmed in early 2024, reflecting improved stability in the U.S. hospital industry.
Read More
The CDC updated 2024 guidance allowing most asymptomatic healthcare workers with high-risk SARS-CoV-2 exposure to continue working without restrictions.
Read More
Nearly half of Americans worry about health care affordability in 2026, with 29% citing cost as the top health issue, per a West Health–Gallup survey.
Read More
Major U.S. hospital systems accelerated outpatient care shifts in 2023 amid new value-based contracts promoting quality over volume.
Read More
Merck and Kelun-Biotech’s Phase 3 trial showed sacituzumab tirumotecan plus KEYTRUDA cut tumor progression risk by 65% in advanced lung cancer patients.
Read More
